Annals of clinical and laboratory science · 2019
Poly (ADP-ribose) polymerase-1 Binding Protein Facilitates Lung Adenocarcinoma Cell Proliferation and Correlates with Poor Prognosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Dong, Tao Zheng, Tang Xing, He Jing-Kang
Аннотация
OBJECTIVE: This study makes a preliminary inquiry on the biological functions of PARPBP in lung adenocarcinoma progression.
METHODS: mRNA expression profiles and clinical data for lung adenocarcinoma and normal lung samples were downloaded from the TCGA database. The expression of PARPBP was analyzed by a student's t test. The survival curve of lung adenocarcinoma patients was drawn using Kaplan-Meier method. A Chi-square test was applied for analyzing the correlation between PARPBP expression and clinical factors. The prognosis value of PARPBP was determined using a cox proportional hazards model. A549 cells with silenced PARPBP were constructed using RNA interference. CCK8 assay and scratch tests were conducted to test the influence of PARPBP on A549 cell proliferation and migration. A Western blot was implemented to examine the changes of p-MEK/MEK and p-ERK/ERK ratios after depleting PARPBP.
RESULTS: PARPBP expression is enhanced in lung adenocarcinoma tissues (p=3.51E-35) and correlates with poor prognosis in lung adenocarcinoma patients (p=0.003). High PARPBP expression is closely correlated with pathologic-stages (p=0.033) and can be utilized as an independent predictor in lung adenocarcinoma patients. Moreover, the knockdown of PARPBP significantly suppressed A549 cell viability and migration (p<0.01). In addition, the ratios of p-MEK/MEK and p-ERK/ERK declined after silencing PARPBP (p<0.01).
CONCLUSIONS: PARPBP expression is enhanced in lung adenocarcinoma tissues and is a potential factor in the progression of lung adenocarcinoma.
METHODS: mRNA expression profiles and clinical data for lung adenocarcinoma and normal lung samples were downloaded from the TCGA database. The expression of PARPBP was analyzed by a student's t test. The survival curve of lung adenocarcinoma patients was drawn using Kaplan-Meier method. A Chi-square test was applied for analyzing the correlation between PARPBP expression and clinical factors. The prognosis value of PARPBP was determined using a cox proportional hazards model. A549 cells with silenced PARPBP were constructed using RNA interference. CCK8 assay and scratch tests were conducted to test the influence of PARPBP on A549 cell proliferation and migration. A Western blot was implemented to examine the changes of p-MEK/MEK and p-ERK/ERK ratios after depleting PARPBP.
RESULTS: PARPBP expression is enhanced in lung adenocarcinoma tissues (p=3.51E-35) and correlates with poor prognosis in lung adenocarcinoma patients (p=0.003). High PARPBP expression is closely correlated with pathologic-stages (p=0.033) and can be utilized as an independent predictor in lung adenocarcinoma patients. Moreover, the knockdown of PARPBP significantly suppressed A549 cell viability and migration (p<0.01). In addition, the ratios of p-MEK/MEK and p-ERK/ERK declined after silencing PARPBP (p<0.01).
CONCLUSIONS: PARPBP expression is enhanced in lung adenocarcinoma tissues and is a potential factor in the progression of lung adenocarcinoma.